5V7 Stock Chart & Stats
€0.05
>-€0.01(-9.68%)
At close: 4:00 PM EDT
€0.05
>-€0.01(-9.68%)
Day’s Range― - ―
52-Week Range€0.04 - €0.09
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€10.25M
Enterprise Value€22.72
Total Cash (Recent Filing)€333.63K
Total Debt (Recent Filing)€2.62M
Price to Earnings (P/E)―
Beta-0.49
Next Earnings
Dec 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding192,877,940
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)-5.63
Price to Sales (P/S)128.71
P/FCF Ratio-14.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthRevenue growth indicates continued expansion in demand for the company’s cardiac imaging analytics offering. If sustained, a growing customer base can improve operating leverage, support broader clinical adoption, and create a stronger foundation for future profitability.
Very High Gross MarginThe very high gross margin suggests the software and diagnostic analytics model has attractive underlying unit economics. This provides substantial potential for incremental revenue to contribute toward operating costs, although the benefit depends on achieving sufficient scale and controlling expenses.
Losses NarrowingMeaningful improvement from the much weaker margins reported in 2023–2024 suggests progress toward reducing the gap between revenue and operating costs. Continued improvement could strengthen financial durability, though the company remains materially below break-even today.
Bears Say
Negative Equity And High LeverageNegative equity and debt that exceeds the reported asset base indicate a highly constrained capital structure. This reduces financial flexibility, increases reliance on external financing, and may limit the company’s ability to fund product development or absorb operating setbacks.
Persistent Cash BurnOngoing negative operating and free cash flow means the business is not yet self-funding its operations. Continued cash consumption can require additional financing and may weaken strategic flexibility, even though the burn rate has improved compared with prior years.
Unprofitable OperationsPersistent negative net, operating, and EBITDA margins show that revenue growth has not yet translated into sustainable earnings. Until the company reaches break-even, it remains exposed to funding pressure and has limited internally generated resources for long-term expansion.
5V7 FAQ
What was VentriPoint Diagnostics Ltd’s price range in the past 12 months?
VentriPoint Diagnostics Ltd lowest stock price was €0.04 and its highest was €0.09 in the past 12 months.
What is VentriPoint Diagnostics Ltd’s market cap?
VentriPoint Diagnostics Ltd’s market cap is €10.25M.
When is VentriPoint Diagnostics Ltd’s upcoming earnings report date?
VentriPoint Diagnostics Ltd’s upcoming earnings report date is Dec 02, 2026 which is in 60 days.
How were VentriPoint Diagnostics Ltd’s earnings last quarter?
VentriPoint Diagnostics Ltd released its earnings results on Sep 01, 2026. The company reported -€0.004 earnings per share for the quarter.
Is VentriPoint Diagnostics Ltd overvalued?
According to Wall Street analysts VentriPoint Diagnostics Ltd’s price is currently Overvalued.
Does VentriPoint Diagnostics Ltd pay dividends?
VentriPoint Diagnostics Ltd does not currently pay dividends.
What is VentriPoint Diagnostics Ltd’s EPS estimate?
VentriPoint Diagnostics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does VentriPoint Diagnostics Ltd have?
VentriPoint Diagnostics Ltd has 192,877,940 shares outstanding.
What happened to VentriPoint Diagnostics Ltd’s price movement after its last earnings report?
VentriPoint Diagnostics Ltd reported an EPS of -€0.004 in its last earnings report. Following the earnings report the stock price went down -5.769%.
Which hedge fund is a major shareholder of VentriPoint Diagnostics Ltd?
Currently, no hedge funds are holding shares in DE:5V7
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
VentriPoint Diagnostics Ltd
VentriPoint Diagnostics Ltd. is a medical technology company focused on developing and commercializing diagnostic tools worldwide. These innovative solutions are designed to monitor individuals afflicted with cardiovascular disease. At the core of their offerings is the Ventripoint Medical System (VMS), an advanced medical imaging platform. The VMS generates precise three-dimensional models of the heart's chambers, providing crucial volumetric and functional measurements. This system is further enhanced by its VMS+ software, which processes echocardiogram and magnetic resonance imaging (MRI) data to construct these 3D models. The VMS+ software ensures highly reproducible and accurate quantification of heart chamber volumes and ejection fraction. Beyond its current flagship system, VentriPoint Diagnostics is actively expanding its portfolio with a suite of specialized applications. These applications target various cardiac conditions and imaging techniques, including congenital heart disease, pulmonary hypertension, cardiotoxicity in oncology patients, and heart complications stemming from Covid-19. Founded in 2004, the company operates from its headquarters in Toronto, Canada.